Metis TechBio Co., Ltd. (HKG:7666)

Hong Kong · Delayed Price · Currency is HKD

15.00

+3.28 (27.99%)

Aug 20, 2026, 4:09 PM HKT

Market Cap	17.74B
Revenue (ttm)	116.85M +18,853.1%
Net Income	-436.04M
EPS	-5.18
Shares Out	1.18B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,626,140
Open	13.47
Previous Close	11.72
Day's Range	13.47 - 15.83
52-Week Range	9.46 - 29.98
Beta	n/a
Analysts	Strong Buy
Price Target	24.69 (+64.6%)
Earnings Date	Aug 25, 2026

About Metis TechBio

Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based life forms in Chinese Mainland and United States. It develops NanoForge, a suite of synergistic technologies that includes novo lipid library, AI foundational models, METiSAIAgent, quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. The company also develops specialized platforms, such as AiTEM, AiLNP and AiRNA that simulate, predict, and interpret nan... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2020

Country China

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 7666

Full Company Profile

Financial Performance

In 2025, Metis TechBio's revenue was 105.00 million, an increase of 6985.02% compared to the previous year's 1.48 million. Losses were -391.84 million, -21.51% less than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 7666 stock is "Strong Buy." The 12-month stock price target is $24.69, which is an increase of 64.60% from the latest price.

Price Target

$24.69

(64.60% upside)

Analyst Consensus: Strong Buy

Stock Forecasts